EntreMed Names Ken K. Ren CEO

EntreMed, Inc. ENMD announced today that its Board of Directors has appointed two new individuals as directors.  Joining the Board are James Huang and Y. Alexander Wu, Ph.D. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) James Huang is Managing Partner of Kleiner Perkins Caufield Byers China and General Partner of KPCB China Fund II, LP, which invested in EntreMed's previously announced registered direct financing that closed in March 2013.  Prior to Kleiner Perkins, Mr. Huang was Managing Partner at Vivo Ventures LLC, a venture capital firm specializing in life science investments.  Mr. Huang has over 20 years of experience in the pharmaceutical and biopharmaceutical industry.  During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp.  Mr. Huang received a B.S. degree in chemical engineering from the University of California, Berkley and a M.B.A. from the Stanford Graduate School of Business.  Y. Alexander Wu, Ph.D. is co-founder and CEO of Crown Bioscience, Inc., a drug discovery and preclinical research organization in the oncology sector with over 300 employees.  Before co-founding Crown See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceManagement
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!